Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07624513 |
| Title | Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Dana-Farber Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Beth Israel Deaconess Medical Center (BIDMC) | NOT_YET_RECRUITING | Boston | Massachusetts | 02115 | United States | Details |
| Brigham and Women's Hospital | NOT_YET_RECRUITING | Boston | Massachusetts | 02115 | United States | Details |
| Dana-Farber Cancer Institute | RECRUITING | Boston | Massachusetts | 02115 | United States | Details |